SCYNEXIS to Participate in H.C. Wainwright Conference and Maxim’s Antifungal Webinar
JERSEY CITY, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc.. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Marco Taglietti, Chief Executive Officer, will participate in a fireside chat at H.C. Wainwright’s 22nd Annual Global Investment Healthcare Conference taking place September 14-16, 2020. Dr. Taglietti will also partake in a panel discussion at Maxim’s antifungal webinar taking place September 17, 2020.
|H.C. Wainwright 22nd Annual Global Investment Conference|
|Presentation Date:||Tuesday, September 15, 2020|
|Presentation Time:||2:30 p.m. ET|
|Maxim’s Antifungal Webinar|
|Webinar Topic:||A Too Quiet Pandemic – Fungal Disease|
|Date:||Thursday, September 17, 2020|
|Time:||11:00 a.m. ET|
|Register to attend via link|
A webcast of the HCW presentation and a recording of the Maxim webinar will be available for 30 days on the SCYNEXIS website at: https://www.scynexis.com/news-media/events
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
Tel: (646) 970-4681
Tel: (646) 970-4688